tetano
Editor, Senior Moderator
Life Sci. 2020 Feb 28:117477. doi: 10.1016/j.lfs.2020.117477. [Epub ahead of print] [h=1]Anti-HCV, nucleotide inhibitors, repurposing against COVID-19.[/h]
Elfiky AA[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]AIMS:[/h] A newly emerged Human Coronavirus (HCoV) is reported two months ago in Wuhan, China (COVID-19). Until today >2700 deaths from the 80,000 confirmed cases reported mainly in China and 40 other countries. Human to human transmission is confirmed for COVID-19 by China a month ago. Based on the World Health Organization (WHO) reports, SARS HCoV is responsible for >8000 cases with confirmed 774 deaths. Additionally, MERS HCoV is responsible for 858 deaths out of about 2500 reported cases. The current study aims to test anti-HCV drugs against COVID-19 RNA dependent RNA polymerase (RdRp).
[h=4]MATERIALS AND METHODS:[/h] In this study, sequence analysis, modeling, and docking are used to build a model for Wuhan COVID-19 RdRp. Additionally, the newly emerged Wuhan HCoV RdRp model is targeted by anti-polymerase drugs, including the approved drugs Sofosbuvir and Ribavirin.
[h=4]KEY FINDINGS:[/h] The results suggest the effectiveness of Sofosbuvir, IDX-184, Ribavirin, and Remidisvir as potent drugs against the newly emerged HCoV disease.
[h=4]SIGNIFICANCE:[/h] The present study presents a perfect model for COVID-19 RdRp enabling its testing in silico against anti-polymerase drugs. Besides, the study presents some drugs that previously proved its efficiency against the newly emerged viral infection.
Copyright ? 2020. Published by Elsevier Inc.
[h=4]KEYWORDS:[/h] COVID-19; Docking; Nucleotide inhibitors; RdRp; Sofosbuvir; Structural bioinformatics; Wuhan coronavirus
PMID: 32119961 DOI: 10.1016/j.lfs.2020.117477
Elfiky AA[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]AIMS:[/h] A newly emerged Human Coronavirus (HCoV) is reported two months ago in Wuhan, China (COVID-19). Until today >2700 deaths from the 80,000 confirmed cases reported mainly in China and 40 other countries. Human to human transmission is confirmed for COVID-19 by China a month ago. Based on the World Health Organization (WHO) reports, SARS HCoV is responsible for >8000 cases with confirmed 774 deaths. Additionally, MERS HCoV is responsible for 858 deaths out of about 2500 reported cases. The current study aims to test anti-HCV drugs against COVID-19 RNA dependent RNA polymerase (RdRp).
[h=4]MATERIALS AND METHODS:[/h] In this study, sequence analysis, modeling, and docking are used to build a model for Wuhan COVID-19 RdRp. Additionally, the newly emerged Wuhan HCoV RdRp model is targeted by anti-polymerase drugs, including the approved drugs Sofosbuvir and Ribavirin.
[h=4]KEY FINDINGS:[/h] The results suggest the effectiveness of Sofosbuvir, IDX-184, Ribavirin, and Remidisvir as potent drugs against the newly emerged HCoV disease.
[h=4]SIGNIFICANCE:[/h] The present study presents a perfect model for COVID-19 RdRp enabling its testing in silico against anti-polymerase drugs. Besides, the study presents some drugs that previously proved its efficiency against the newly emerged viral infection.
Copyright ? 2020. Published by Elsevier Inc.
[h=4]KEYWORDS:[/h] COVID-19; Docking; Nucleotide inhibitors; RdRp; Sofosbuvir; Structural bioinformatics; Wuhan coronavirus
PMID: 32119961 DOI: 10.1016/j.lfs.2020.117477